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Genomic alterations in the p53 tumour-suppressor gene and overexpression of p53 protein, resulting from
gene mutations, are frequently found in pancreatic cancer. In this study we analysed the sera of 160 patients
with malignant and benign pancreatic diseases for the presence of circulating antibodies to the p53 protein.
The analysis of the sera was performed using two different enzyme-linked immunosorbent assay (ELISA)
systems. To further substantiate the results, all sera were analysed by the Western blot technique using a cell
lysate of PancTu-I cells (p53 mutation at codon 176) as antigen source. Additionally, all positive sera were
analysed by the Western blot technique using recombinant p53 as the antigen source. Although the rate of p53
mutations in pancreatic tumours is of the same order as in other adenocarcinomas (>,50%), an antibody
response was found in only 5/78 (6.4%) sera from patients with pancreatic cancer. Two out of 82 (2.4%) sera
of patients with benign pancreatic diseases were clearly positive for p53 antibodies. One additional specimen
was weakly positive, i.e. only in one ELISA and Western blot system.
The p53 tumour-suppressor gene encodes a 53 kDa nuclear
phosphoprotein which is thought to protect cells against the
accumulation of genetic alterations. Overexpression of the
wild-type (wt) p53 protein and an increase in transcriptional
transactivation activity, following treatment with DNA-
damaging agents, lead to cell cycle arrest in the GI phase or
the induction of apoptosis. (Vogelstein & Kinzler, 1992;
Lane, 1993; Levine et al., 1994). Abnormalities in the p53
gene are the most common genetic alteration in human
cancer (Hollstein et al., 1991; Levine et al., 1991; Caron de
Fromentel & Soussi, 1992). In normal tissue wt p53 protein is
difficult to detect, whereas in cells with p53 gene mutations,
conformational changes and a prolonged biological half-life
lead to accumulation of mutant p53 protein.
In human pancreatic cancer, genomic alterations in the p53
tumour-suppressor gene are frequently combined with muta-
tions in the c-K-ras oncogene. Summarising the data from six
groups (Barton et al., 1991; Ruggeri et al., 1992; Casey et al.,
1993; Kalthoff et al., 1993; Scarpa et al., 1993; M. Perucho,
personal communication) the mutation pattern of the p53
gene in pancreatic cancer shows a similar distribution to
other gastrointestinal adenocarcinomas, with hotspots at
positions 273, 248, 175 and additionally at positions 220 and
132.
Alterations of p53 cannot only be detected with molecular
biological and immunohistochemical methods. In addition,
mutant p53 proteins may serve as targets of the host immune
system as tumour-specific antigens (Harris & Hollstein,
1993). Several previous studies have described the detection
of antibodies against p53 protein in the sera of patients with
various malignant diseases (Crawford et al., 1982, 1984;
Caron de Fromentel et al., 1987; Davidoff et al., 1992;
Hassapoglidou & Diamindis, 1992; Schlichtholz et al., 1992;
Winter et al., 1992; Volkmann et al., 1993).
The aim of this study was to investigate whether p53-
specific antibodies could be found in the sera of patients with
malignant and benign pancreatic diseases, since in previous
analyses (Kalthoff et al., 1993) we were able to show specific
p53 immunoreactivity in cytospin preparations derived from
patients with pancreatic cancer and, in addition, in specimens
from patients with acute and chronic pancreatitis.
The analysis of 160 sera was performed using two
independently developed ELISA systems. To further substan-
tiate the results, all sera were analysed by Western blot
technique using a cell lysate of PancTu-l cells (p53 mutation
Correspondence: H. Kalthoff.
Received 25 May 1994; and in revised form 12 July 1994.
at codon 176) as the antigen source. Additionally, all positive
sera were analysed by Western blot technique using recom-
binant p53 as the antigen source. We found p53 antibodies in
the sera of 5/78 pancreatic tumour patients and in the sera
2/,82 of patients with benign pancreatic diseases. Two other
specimens from this group tested positive, one with only
weak reactivity and the other derived from a patient suffering
from a squamous epithelial carcinoma of the tongue in addi-
tion to having chronic pancreatitis.
Materiais and methoi
Patient groups
Serum samples from 78 patients with pancreatic cancer were
analysed. In 60 patients a tissue diagnosis was obtained. In
57 patients with a malignant tumour the diagnosis was histo-
logically proven adenocarcinoma; three patients had endo-
crine tumours. Tissue samples were not available in some
patients (18) with inoperable cancer who underwent either
palliative surgery or endoscopic drainage.
Serum samples of 82 patients with benign pancreatic
diseases were analysed in this study. Of these 37 had chronic
pancreatitis. The diagnosis of chronic pancreatitis was based
on the presence of calcifications, pseudocysts, stenosis or
destruction of the pancreatic duct at endoscopic retrograde
cholangiopancreatography (ERCP). In 27 patients the pan-
creatitis was not a first-time event, but no gross structural
changes of the pancreas were recorded in these cases. The
diagnosis was based on typical clinical signs such as case
history, symptoms, elevation of amylase and lipase. Eighteen
of the patients had an acute pancreatitis and no medical
history of previous pancreatic diseases.
ELISA systems
An anti-p53 autoantibody sandwich ELISA with solid-phase
recombinant p53 protein was purchased from Dianova
(Hamburg, Germany) and the analyses of the sera performed
according to the manufacturer's recommendations. All sera
were analysed in a second ELISA system kindly provided by
T. Soussi, Paris (Schlichtholz et al., 1994).
Cell line and culture conditions
The human pancreatic cell line PancTu-l (Dr M. v. Builow,
Mainz, Germany) was routinely cultured in RPMI-1640
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medium, supplemented with 10% fetal bovine serum (FBS),
2 mM glutamine, 1 mM sodium pyruvate, 100 U ml1' penicil-
lin and 100 U ml-' streptomycin (all from Life Technologies,
Eggenstein, Germany). The cells were grown to approxi-
mately 70-90% confluence at 3TC with 5% carbon
dioxide.
Solubilisation
Cells were washed once with ice-cold phosphate-buffered
saline (PBS). Subsequently, cells were washed twice with cell
wash buffer [ice-cold PBS, containing 1.5 mM EDTA, 100liM
phenyl methyl sulphonyl fluoride (PMSF), 1 gLg ml-'
aprotinin (Trasylol), adjusted to pH 7.4] and then
resuspended in cell wash buffer. The cell suspension was
centrifuged for 4 min at 1,400 r.p.m. and the cell pellet
resuspended in lysis buffer [10 mM TRIS, containing 1.5 mM
EDTA, 100 im PMSF, 1 igml1l aprotinin (Trasylol)
adjusted to pH 7.4]. The cell suspension was incubated for
5 min at 4°C with occasional gentle mixing, followed by the
addition of 20 gil of AEA (Antigen Extraction Agent,
Oncogene Science, Dianova) for every 100 il of cell suspen-
sion, with further incubation for 5 min at 4'C and occasional
vortexing. The extracts were transferred to microcentrifuge
tubes and centrifuged at 4°C for 15 min at 14,000 r.p.m. The
supernatant was collected and retained for protein determina-
tion and Western blotting.
The protein content of the cellular extracts was measured
by the BCA Protein Assay (Pierce, Rockford, IL, USA).
Western blot
PancTu-l cell lysate and recombinant wt p53 protein, kindly
provided by W. Deppert (HPI, Hamburg, Germany), were
electrophoretically separated by SDS-PAGE in a 10% gel
and subsequently transferred to nitrocellulose filters.
After blotting, the nitrocellulose sheets were blocked in 5%
bovine serum albumin (BSA) in PBS for 3 h at room
temperature. The sheets were washed three times for 5 min
with washing buffer (PBS, 0.05% Tween 20). Strips were
incubated with the primary antibodies for 2 h and 30 min at
room temperature on a rocking platform. As positive con-
trols we used MAb 1801 (Oncogene Science, Dianova) and
PAb HSP 53/2 (IgG fraction of a rabbit, hyperimmunised
with recombinant wt p53 protein). All serum samples were
diluted 1:100 in PBS containing 5% BSA. Following the first
incubation, the strips were washed three times for 5 min with
washing buffer (PBS, 0.05% Tween 20). As secondary anti-
bodies - corresponding to the first antibodies - we used a
peroxidase-conjugated AffiniPure F(ab')2 fragment of goat
anti-human IgA + IgG + IgM (H + L), a peroxidase-
conjugated AffiniPure F(ab% fragment of goat anti-mouse
(H + L) and a peroxidase-conjugated AffiniPure goat anti-
rabbit IgG F(ab% fragment (all from Jackson Immuno-
research Laboratories, USA), which were diluted 1:1,000 in
PBS containing 5% BSA. Incubation was performed on a
rocking platform for 1 h at room temperature. The subse-
quent washing steps were performed as described above. To
visualise the reaction, the strips were incubated in a reagent
comprising 4 ml of 4-chloro-1-naphthol [0.3% (w/v) in
methanol] and 20 ml of substrate buffer (20 mM) Tris pH 7.4,
150 mM sodium chloride) and 6 gil of hydrogen peroxide
(30%, v/v). The reaction was stopped with distilled water.
Results
In both the independently developed ELISA systems, 5 of 78
serum samples from patients with pancreatic cancer were
positive for anti-p53 antibodies (Table Ia). Specimens which
were positive by the ELISA methods were confirmed by the
Western blot techniques using PancTu-I cell lysate (Figure 1)
and recombinant wt p53 protein (Figure 2) as antigen
sources. In all five patients the tumour had metastasised into
the liver. In two of the patients a histological tissue diagnosis
was available and showed an adenocarcinoma. Four of the
patients were males. The age ranged from 45 to 72 years with
a median of 59.4 years. All five patients had high CA 19/9
levels and three patients had high CEA levels. All five
patients died within 7 months after the pancreatic cancer was
diagnosed (the survival time ranging from 2 to 7 months).
Seventy-three serum samples from patients with pancreatic
cancer were negative in both ELISA systems and confirmed
by Western blot technique. In 67 of the 73 p53 antibody-
negative patients with pancreatic cancer the tumours had
metastasised into the liver as well. In 58 of the patients a
tissue diagnosis was obtained fifty-five were classified as
adenocarcinomas and three as endocrine tumours. Fifty-two
Table I Detection of anti-p53 antibodies in human sera
PancTu wt p53 CEA CA 1919
Sera Assai 1 Assay 2 WB WB (ngmt') (Uml-,
(a) Pancreatic carcinoma
1254 + + + + + + ND 21,7 23,114
2437 + + + + 2 6,300
2804 + + + + + + + 2,443 20,570
3622 ++ +++ +++ +++ 5 141
3632 + + + + 42 5,760
(b) Benign pancreatic diseases
2.360 + - + + + ND ND
2.722 + + + ++ 2.7 338
1.134 + - - ND ND
1.154 + - - + ND ND
1033- + + + + + ND 11
(a) Results of the serum sample analysis of five patients with malignant pancreatic diseases
which were considered positive. Serum samples from 73 patients with negative results are not
listed.
(b) Results of the serum sample analysis of two patients with benign pancreatic diseases
which were considered positive and two further samples from one patient (1,134 and 1,154)
which scored differently in the various assays.
'This sample was obtained from a patient suffering from squamous epithelial carcinoma of
the tongue in addition to chronic pancreatitis. Serum samples from 78 patients with negative
results are not listed.
In assay I (Dianova) positivity was evaluated as recommended by the manufacturer
yielding the following categories: +, low; + +, medium; + + +, high expression. Assay 2
(Th. Soussi. Paris): +. dil. 1:100; ++. dil. 1:300; +++, dil. 1:800. Western blot (WB)
analysis: +. low: + +. clear, + + +, strong signal; ND, not done.ANTI-p53 IN PANCREATIC DISEASE 1633
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Figme 1 Wester blot analyses of serum samples (1:100) using
PancTu-l cel lysate as the antigen source. As a positive control
MAb 1801 and PAb HSP 53/2 (IgG fraction of a rabbit, hyper-
immunised with recombinant wt p53 protein) were used. 'control'
means negative control, omitting the first antibody. Sera 457 and
1,419 represent negative specimens. Sera 2,804 and 2,811 are
samples from the same patient collected independently at
different times (sera 3,622 and 3,627 likewise). These parallel
samples served as internal references.
53 kDa-
Fugwe 2 Western blot analyses of sern samples (1:100) using
recombinant wt p53 protein as the antigen source. MAb 1801
served as a positive control, as a negative control human serum
3,522 was used.
patients were males. The age ranged from 40 to 77 years with
a median of 60.4 years. Sixty-seven patients had either high
CEA or high CA 19/9 levels or both (data not shown).
In the group of patients with benign pancreatic disease,
one patient with chronic and one with actue pancreatitis were
positive for p53 antibodies (Table lb). One patient (serum
no. 2,360) with acute pancreatitis and no previous history of
pancreatic disease tested positive in the ELISA system from
Dianova, but not in the other ELISA system. Both Western
blot techniques showed a clear reaction (Figures I and 2). At
the time of serum sample collection this patient was
suspected of having autoimmune hepatitis. One patient
(serum no. 2,722) with acute pancreatitis, a prior history of
pancreatitis and no signs of malignancy on ERCP or endo-
scopic ultrasonography, and who died from septic shock 1
month after admission to hospital, was positive in both
ELISA systems (Table lb). A reaction was seen with the
Western blot technique using PancTu-I cell lysate as the
antigen source and was confirmed by a strong signal in the
Western blot with the recombinant wt p53 (Figures 1 and 2).
One patient (serum no. 1,033) with a chronic pancreatitis was
positive in both ELISA systems and showed strong reactions
in both Western blot systems (Table Tb, Figures 1 and 2).
This patient had a squamous epithelial carcinoma of the
tongue at the time of sample collection. Since the squamous
epithelial carcinoma as well as the chronic pancreatitis could
have been the reason for the anti-p53 positivity the patient's
data are listed separately in Table lb.
In addition to the three patients described above, one
patient (sera nos. 1,134 and 1,154) had a chronic pancreatitis
and no malignancy or any other disease at the time of serum
collection. A resection of the pancreatic head (partial
duodenopancreatectomie) was performed 6 months later and
histology only revealed characteristics of an advanced
chronic pancreatitis. No signs of malignancy were recorded.
The serum samples were positive in the Dianova ELISA
system, but showed no clear reaction in the other ELISA
system. No reaction was seen with the Western blot tech-
nique using the PancTu-l cell lysate, but a faint reaction was
seen with the recombinant p53 (Table lb, Figures 1 and
2).
Discossdo
The results of the two independently developed ELISA
systems for the detection of antibodies against p53 correlated
well, both with each other and with the Western blot analysis
using PancTu-l cell lysate and recombinant wt p53 as the
antigen source.
Although the rate of p53 mutations in pancreatic tumours
is of the order of that in other adenocarcinomas (>,50%),
only a few cases of antibody response were found in this
study. Antibodies against p53 were detected in 5/78 patients
(6.4%) with pancreatic cancer. The detection rate for
antibodies against p53 was reported to be 9-14% in breast
cancer (Crawford et al., 1982; Caron de Freomentel et al.,
1987; Davidoff et al., 1992; Schlichtholz et al., 1992), 10% in
lung cancer (Winter et al., 1992), 12.5% in colorectal cancer
(Crawford et al., 1984), 20% in B-cell lymphoma (Caron de
Fromentel et al., 1987) and 20% in hepatocellular carcinoma
(Volkmann et al., 1993).
In an analysis of 790 serum samples from patients with
various malignancies, only 16 positive samples (2%) were
identified by Hassapoglidou and Diamandis (1992). The
prevalence of p53 antibodies in the patients with pancreatic
cancer in our study is lower than in serum samples of
patients with colorectal cancer (Crawford et al., 1984),
despite the fact that the rate of p53 gene mutations in
colorectal and pancreatic cancer is very similar, suggesting
either a particular mutation pattern in pancreatic cancer with
low immunogenicity or a generally suppressed immune
system in these patients. Complexes between p53 protein and
a 70kDa heat shock protein might be necessary for the
antigenic presentation of p53 (Davidoff et al., 1992). This
putative prerequisite may only be fulfilled in a few pancreatic
carcinomas.
In previous analyses (Kalthoff et al., 1993; Kessler et al.,
1993) we were able to show specific p53 immunoreactivity in
cytospin preparations derived from patients with pancreatic
cancer (7/10) and, in addition, in specimens from patients
with acute and chronic pancreatitis (9/13). The fact that
antibodies against p53 were found in serum samples of
patients with non-malignant pancreatic diseases may point to
a p53 release and antigen processing with subsequent elicita-
tion of a p53-directed antibody response by necroinflam-
matory benign diseases. Another hypothesis to explain the
occurrence ofp53 antibodies in these patients is the presence
of as yet undetected malignancies.
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